Therefore, low serum CRP levels in ccRCC patients undergoing anticancer therapy may enhance the efficacy of therapy, wherein CD64 may be a novel therapeutic target for ccRCC. The gene discussed is FCGR1A; the disease is nonpapillary renal cell carcinoma.